103 related articles for article (PubMed ID: 26680099)
1. Overexpression of the BRIP1 ameliorates chemosensitivity to cisplatin by inhibiting Rac1 GTPase activity in cervical carcinoma HeLa cells.
Liu Y; Li H; Zhang R; Dang H; Sun P; Zou L; Zhang Y; Gao Y; Hu Y
Gene; 2016 Mar; 578(1):85-91. PubMed ID: 26680099
[TBL] [Abstract][Full Text] [Related]
2. Effect of Rac1 downregulation mediated by shRNA on the biological behaviour of human cervical cancer cells.
Xu AL; Yu GQ; Kong XC; Qiu XH; Li PL
J Int Med Res; 2013 Aug; 41(4):1037-48. PubMed ID: 23760915
[TBL] [Abstract][Full Text] [Related]
3. SH3BP1-induced Rac-Wave2 pathway activation regulates cervical cancer cell migration, invasion, and chemoresistance to cisplatin.
Wang J; Feng Y; Chen X; Du Z; Jiang S; Ma S; Zou W
J Cell Biochem; 2018 Feb; 119(2):1733-1745. PubMed ID: 28786507
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
[TBL] [Abstract][Full Text] [Related]
5. BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity.
Zou W; Ma X; Hua W; Chen B; Huang Y; Wang D; Cai G
Oncol Lett; 2016 Jan; 11(1):551-558. PubMed ID: 26870246
[TBL] [Abstract][Full Text] [Related]
6. Doxycycline Induces Apoptosis and Inhibits Proliferation and Invasion of Human Cervical Carcinoma Stem Cells.
Yang B; Lu Y; Zhang A; Zhou A; Zhang L; Zhang L; Gao L; Zang Y; Tang X; Sun L
PLoS One; 2015; 10(6):e0129138. PubMed ID: 26111245
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
8. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.
Yang L; Shi T; Liu F; Ren C; Wang Z; Li Y; Tu X; Yang G; Cheng X
PLoS One; 2015; 10(3):e0120334. PubMed ID: 25781640
[TBL] [Abstract][Full Text] [Related]
9. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
[TBL] [Abstract][Full Text] [Related]
10. Dual apoptotic effect of Xrel3 c-Rel/NF-kappaB homolog in human cervical cancer cells.
Shehata M; Shehata M; Shehata F; Pater A
Cell Biol Int; 2004; 28(12):895-904. PubMed ID: 15566959
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines.
García-López P; Rodríguez-Dorantes M; Pérez-Cárdenas E; Cerbón M; Mohar-Betancourt A
Cancer Chemother Pharmacol; 2004 Jun; 53(6):533-40. PubMed ID: 15138713
[TBL] [Abstract][Full Text] [Related]
13. Improved chemosensitivity in cervical cancer to cisplatin: synergistic activity of mahanine through STAT3 inhibition.
Das R; Bhattacharya K; Samanta SK; Pal BC; Mandal C
Cancer Lett; 2014 Aug; 351(1):81-90. PubMed ID: 24831030
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
Koivusalo R; Krausz E; Helenius H; Hietanen S
Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
[TBL] [Abstract][Full Text] [Related]
15. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
[TBL] [Abstract][Full Text] [Related]
16. Aberrantly Expressed Timeless Regulates Cell Proliferation and Cisplatin Efficacy in Cervical Cancer.
Zhou J; Zhang Y; Zou X; Kuai L; Wang L; Wang J; Shen F; Hu J; Zhang X; Huang Y; Chen Y
Hum Gene Ther; 2020 Mar; 31(5-6):385-395. PubMed ID: 31870179
[TBL] [Abstract][Full Text] [Related]
17. L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation.
Wagner W; Ciszewski WM; Kania KD
Cell Commun Signal; 2015 Jul; 13():36. PubMed ID: 26208712
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells.
Zhang X; Pan C; Zhou L; Cai Z; Zhao S; Yu D
BMC Cancer; 2016 Dec; 16(1):949. PubMed ID: 27986075
[TBL] [Abstract][Full Text] [Related]
19. Involvement of Src signaling in the synergistic effect between cisplatin and digoxin on cancer cell viability.
Pereira DG; Salgado MAR; Rocha SC; Santos HL; Villar JAFP; Contreras RG; Fontes CFL; Barbosa LA; Cortes VF
J Cell Biochem; 2018 Apr; 119(4):3352-3362. PubMed ID: 29130514
[TBL] [Abstract][Full Text] [Related]
20. HeLa human cervical cancer cell migration is inhibited by treatment with dibutyryl-cAMP.
Lee JW; Lee J; Moon EY
Anticancer Res; 2014 Jul; 34(7):3447-55. PubMed ID: 24982353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
